Static No More? Biopharma Shifts Towards Payer Portals for HCEI Deliver

What platforms are biopharmaceutical manufacturers using to disseminate healthcare economic information (HCEI) and Food & Drug Administration Modernization Act (FDAMA) resources? Historically, standard static formats—such as PDFs, Excel models, and PowerPoint presentations—have dominated. While these remain widely used, new survey data suggests that manufacturers are beginning to adopt more dynamic, digital alternatives.

According to a recent survey conducted by BluePath, approximately one-third of manufacturers now use payer portals to deliver HCEI and related evidence materials to population health decision-makers, including insurers, pharmacy benefit managers (PBMs), integrated delivery networks (IDNs), and hospitals.

In addition to payer portals, nearly 20% of manufacturers report using HCEI-specific websites to share real-world evidence. These findings point to a growing trend: manufacturers are increasingly leveraging digital platforms to enhance the reach, accessibility, and impact of their HCEI/FDAMA communications.

The Role of HCEI

The development and dissemination of HCEI is essential for securing and maintaining brand access and reimbursement. As the healthcare landscape becomes more data-driven, the ability to deliver timely, relevant, and credible economic evidence is a strategic imperative.

At BluePath, we work closely with population health decision-makers and support manufacturers in implementing innovative dissemination strategies tailored to their needs.

Interested in learning more?

Contact us at info@bluepathsolutions.com for insights into our work and additional findings from our study on HCEI and FDAMA 114 development and dissemination trends.